Renal Biomarkers Market - Growth, Trends, and Forecasts (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||567962|
|出版日期||內容資訊||英文 119 Pages
|腎障礙生物標記的全球市場 Renal Biomarkers Market - Growth, Trends, and Forecasts (2020 - 2025)|
|出版日期: 2020年08月01日||內容資訊: 英文 119 Pages||
The global renal biomarkers market has been witnessing a CAGR of 7.2%. The key factors propelling the growth of this market are the rising prevalence of various kidney-related diseases, the high prevalence of diabetes and high blood pressure, which are the leading causes of renal diseases, and rapid technological advancements in the field of genetics.
Functional Biomarker is Expected to Hold a High Market Share in the Biomarker Type Segment
In the biomarker type, the functional biomarker is believed to have the largest market share. Chronic kidney disease (CKD) has become a public health problem. According to the National Institute of Diabetes, Digestives, and Kidney Diseases, the overall prevalence of CKD in the general population is approximately 14%, and around 6,61,000 Americans have kidney failure. Currently, the diagnosis of CKD is made by the testing of levels of serum creatinine (SCr). The serum creatinine, a functional biomarker, dominates the market for renal biomarkers, owing to the high prevalence rate of CKD and high presence and knowledge of serum creatinine biomarkers.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for renal biomarkers, and it is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. In the past decade, there was a significant increase in the number of USFDA-approved drug labels containing information on molecular biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or through other ventures.
Molecular biomarkers are expected to be identified and validated in drug development and used to support the approval of drug products. Such drug approvals are helping the renal biomarkers market grow in the United States.
The renal biomarkers market is highly competitive and consists of several major players, along with multiple smaller companies. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new technologies at affordable prices. Companies, like Thermofisher Scientific, Abbott Laboratories, Siemens Healthcare, F. Hoffmann-La Roche, and BioMerieux, hold substantial shares in the market.